SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...

SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Joon Kyung Kim discussing an evaluation of ...

The cohort had a median age of 65 years (IQR 53–68), with 74% male and 82% Caucasian. Of the total 808 gene panel, 15 genes were mutated by >5% in the entire cohort, with PBRM1, SETD2, KDM5C, TP53, ...

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.

Patients with low-grade upper tract urothelial carcinoma receiving primary treatment with 6 once-weekly pyelocalyceal doses ...

(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Peter Clark discussing a first-in-human study of TAR-210 erdafitinib intravesical system in ...

(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Jonathan Ryan ...

SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for non muscle invasive ...

SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Arjun Pon Avudaiappan discussing survival outcomes of radical prostatectomy versus dose-escalated radiation with ADT ...

ERG positivity, an early molecular alteration in prostate cancer development, exhibits differing prevalence between African American and White patients. Nevertheless, the extent of race-based ...

SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Abhi Moolupuri discussing a PET/CT supplemented approach to omission of pelvic lymph node dissection. The National ...

For patients with metachronous low burden mCSPC on conventional imaging being recommended for systemic therapy, 51% responded ...